The increase is almost doubled! Since December, the market prices of many Chinese medicinal materials have risen sharply

Since December, the prices of Chinese medicinal materials such as honeysuckle, banlan root, parsnip, skullcap, licorice, reed root, etc. have risen sharply, and the market price of some medicinal materials has nearly doubled in half a month.

Some insiders said that forsythia was sold for 120 yuan / kg in the early stage, and now the highest price has reached 240 yuan / kg; Honeysuckle sold for 140 yuan/kg in the early stage, and is now close to 300 yuan/kg; The lowest amount of Banlangen before was 10.5 yuan/kg, but now it costs 20 yuan/kg; Ashigen used to sell for 10 yuan/kg, and now it sells for about 22 yuan/kg.

In addition, data show that as of December 14, the unified price of honeysuckle in Hebei was between 200 yuan / kg and 210 yuan / kg, an increase of 46.43% compared with the beginning of the month; The price of forsythia green boiled goods was 200 yuan/kg to 235 yuan/kg, an increase of 77.55% compared with the beginning of the month. The price of patchouli rose from 11 yuan/kg to 22 yuan/kg, an increase of 100%.

For the price increase of some medicinal materials, some insiders said that now all channels are concentrated on a large number of goods, and the market is in short supply in a short period of time, resulting in a rapid rise in prices. In the later stage, it depends on whether demand can be sustained, if not, it may only be a temporary phased rise. The person also said that in recent years, due to the reduction of forsythia production, the inventory was already small. Although the supply of honeysuckle and skullcap is relatively abundant, the surge in demand in a short period of time has also led to higher prices. In addition, in fact, most of the medicinal materials are still relatively sufficient at this time.

In addition, some people said that with the optimization of epidemic prevention and control policies, coupled with the significant increase in people's demand for seasonal standing drugs in winter, drug manufacturers have concentrated on purchasing raw materials of Chinese medicinal materials, resulting in the opening of the 'fast-moving consumer goods' model from APIs to finished products to chain pharmacies, and the market prices of Chinese medicinal materials for heat and detoxification continue to rise.

At present, although the price of some medicinal materials has risen, a number of listed companies have said that they have not been affected. Some companies said that at present, the company's raw material inventory of related products is relatively sufficient, which can support the current expansion demand. The company has built and laid out more than 250,000 mu of planting bases for Chinese medicinal materials, and has sufficient safety stock preparation every year, and continues to replenish rolling procurement under the premise of ensuring safety stock.

In addition, some listed companies said that the company has a forsythia planting base, and the Chinese medicinal materials in the company's inventory are calculated according to the cost price at the time of purchase. The market expects that the company's inventory has increased significantly, and the company's share price has risen sharply recently.

The so-called Chinese medicinal materials refer to the raw materials of Chinese medicines that are unprocessed or unfinished and can be used for medicine, usually from natural plants, animals and minerals.

Recently, with the optimization of epidemic prevention and control policies and the arrival of winter, the demand for related drugs has increased significantly. On the whole, data show that the price of the comprehensive 200 market price index of Chinese medicinal materials changed on December 14; The market price index of the Comprehensive 200 Chinese Materia Medica 200 rose to 2784.70 on December 14, up 0.72% on the day, 4.42% weekly and 4.33% monthly.

Analysts pointed out that the overall supply and demand of the Chinese herbal medicine market is balanced, but the supply and demand of various Chinese medicine varieties vary greatly. Affected by a combination of factors, the overall price of Chinese medicinal materials has increased significantly in recent years, and Chinese herbal medicine raw material trading enterprises and Chinese medicine production enterprises with planting bases for Chinese medicinal materials raw materials directly benefit.

It is predicted that in the future, due to the depletion of wild medicinal materials resources, the rapid development of downstream Chinese herbal tablets and Chinese proprietary medicine industry under the policy dividend, resulting in the growth of demand for Chinese medicinal materials, it is expected that the price of Chinese medicinal materials will enter an upward channel, and the operating performance and overall credit level of Chinese herbal medicine raw material manufacturers are expected to improve.